In 2022, ASCO launched living clinical practice guidelines for systemic therapy for patients with stage IV non–small cell lung cancer (NSCLC) with 1 and without 2 driver alterations. Both have been ...

Human epidermal growth factor receptor 2 (HER2)–positive breast cancer (HER2+BC) is linked to poorer outcomes. Trastuzumab is the standard treatment, but its high cost limits access in ...

Myelodysplastic syndromes (MDS) are a heterogeneous group of diseases that are prognostically stratified into lower-risk (LR-MDS) and higher-risk MDS on the basis of the International Prognostic ...

PURPOSEUp to 30% of patients with metastatic castration-resistant prostate cancer (mCRPC) have DNA damage repair (DDR) gene alterations, mainly in BRCA2. PARP inhibitors (PARPi) are standard ...

This study investigates the incidence and clinicopathologic characteristics of head and neck cancer (HNC) in the Surinamese population, with an emphasis on the burden of human papillomavirus (HPV) and ...

Reducing Fluorouracil Doses in Patients With Partial Dihydropyrimidine Dehydrogenase Deficiency Is a Treatment Safety Strategy, Not a Panacea of Precision Dosing The following represents disclosure ...

A rather interesting and thought-provoking finding from their study is the differential responses seen with respect to prior exposure to PARP inhibition. No responses were observed in 16 DDR+ patients ...

PURPOSETo develop and validate an algorithm to extract clinically relevant data elements for prostate cancer (PCa) from prostate biopsy reports and magnetic resonance imaging (MRI) reports.PATIENTS ...